XML 209 R168.htm IDEA: XBRL DOCUMENT
v3.20.2

Subsequent Events (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) - USD ($) | Sep. 30, 2020 | Sep. 24, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Dec. 31, 2018
--- | --- | --- | --- | --- | ---
Debt instrument principal amount | $ 3,350,100 |  |  |  |
Brooklyn Immunotherapeutics, LLC [Member] |  |  |  |  |
Cash received | $ 3,055,012 |  | $ 5,014,819 | $ 6,260,338 | $ 6,325,431
Brooklyn Immunotherapeutics, LLC [Member] | Subsequent Event [Member] |  |  |  |  |
Debt instrument principal amount |  | $ 3,858,750 |  |  |
Cash received |  | $ 3,858,750 |  |  |

X
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 45 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840 + Details
Name: | us-gaap_Cash
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |